November 19 2024 GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia November 12 2024 GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update November 05 2024 GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 October 02 2024 GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 03 2024 GeoVax to Participate in Upcoming Investor Conferences in September August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 12 2024 GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update November 05 2024 GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 October 02 2024 GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 03 2024 GeoVax to Participate in Upcoming Investor Conferences in September August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 05 2024 GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 October 02 2024 GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 03 2024 GeoVax to Participate in Upcoming Investor Conferences in September August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 02 2024 GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference September 03 2024 GeoVax to Participate in Upcoming Investor Conferences in September August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 03 2024 GeoVax to Participate in Upcoming Investor Conferences in September August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 28 2024 GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 21 2024 Registration Is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 20 2024 GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 15 2024 GeoVax to Present at the Emerging Growth Conference on August 21, 2024 August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 08 2024 GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 06 2024 GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 31 2024 GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 30 2024 GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024 July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 16 2024 GeoVax to Present at the Emerging Growth Conference on July 18, 2024 July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 11 2024 GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 09 2024 GeoVax Provides First Half 2024 Business Update June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 27 2024 GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 18 2024 GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 29 2024 GeoVax to Present at BIO International Convention 2024 May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 17 2024 GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 14 2024 GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 07 2024 GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 04 2024 GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 28 2024 GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 12 2024 GeoVax to Present at the 36th Annual Roth Conference March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 06 2024 GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 29 2024 GeoVax Reports 2023 Year-End Financial Results and Provides Business Update February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 22 2024 GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 19 2024 GeoVax to Present at the 2024 BIO CEO & Investor Conference February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 13 2024 GeoVax Announces Multiple Patent Issuances and Allowances February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 06 2024 GeoVax Reports Positive Interim Data from Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 29 2024 GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 08 2024 GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 04 2024 GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 03 2024 GeoVax Announces Issuance of Malaria Vaccine Patent December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
December 27 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024 December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
December 19 2023 GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 30 2023 GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 29 2023 GeoVax to Participate in Upcoming December Investor Events November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 28 2023 GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 14 2023 Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023 November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 08 2023 GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 31 2023 GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023 October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 30 2023 GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 25 2023 GeoVax to Participate in Upcoming November Investor and Industry Events October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 24 2023 GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 09 2023 GeoVax Receives Notice of Allowance for Marburg Vaccine Patent October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 05 2023 GeoVax Receives Notice of Allowance for HIV Vaccine Patent September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 27 2023 GeoVax to Participate in Upcoming October Investor and Industry Events September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 26 2023 GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 20 2023 GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 19 2023 GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 12 2023 GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 11 2023 GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 31 2023 GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 29 2023 GeoVax to Present at the Emerging Growth Conference on September 6, 2023 August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 28 2023 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 10 2023 GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 09 2023 GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 26 2023 GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023 July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 24 2023 GeoVax Announces Issuance of Ebola Vaccine Patent July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 20 2023 GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 10 2023 GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 28 2023 GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 27 2023 GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 31 2023 GeoVax Partners with ABL to Advance cGMP Production of Vaccine Candidates May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 25 2023 GeoVax to Participate in Upcoming Industry Meetings May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 24 2023 GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 15 2023 GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 09 2023 GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 04 2023 GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 26 2023 GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 25 2023 GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023 April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 19 2023 GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 06 2023 GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 05 2023 GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 30 2023 GeoVax to Participate at the World Vaccine Congress with Multiple Presentations March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 23 2023 GeoVax Reports 2022 Year-End Financial Results And Provides Corporate Update March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 15 2023 GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 09 2023 GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 26 2023 GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 15 2023 GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 08 2023 GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 07 2023 GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 26 2023 GeoVax to Present at the 2023 BIO CEO & Investor Conference January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 25 2023 GeoVax Receives Notice of Allowance for Zika Vaccine Patent January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 04 2023 GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023 December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
December 20 2022 Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
December 07 2022 GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 28 2022 GeoVax to Present at the World Vaccine & Immunotherapy Congress West Coast 2022 November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
November 09 2022 GeoVax Reports 2022 Third Quarter Financial Results and Provides Corporate Update October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 26 2022 GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022 October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 11 2022 GeoVax to Present at Vaccines Summit-2022 October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
October 06 2022 GeoVax to Present at Upcoming Investor Conferences September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 07 2022 GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
September 01 2022 GeoVax Announces Addition to its Board of Directors August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
August 03 2022 GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 28 2022 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Sudan Ebolavirus Showing 100% Protection with a Single Immunization July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
July 26 2022 GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 13 2022 GeoVax Appoints Recognized Industry Leader John W. Sharkey, PhD as Vice President, Business Development June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
June 07 2022 GeoVax to Present at BIO International Convention 2022 May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 25 2022 GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement
